Clinical trials: Severe ARDS
Covid19 Pneumonia
Prevention of COVID-19 Infection to Severe Pneumonia or ARDS
A trial of EC-18 in patients with mild/moderate pneumonia due to COVID-19
- Trial name
- NCT04569227
- Testing
- EC-18
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Enzychem Lifesciences Corporation
Community-acquired Pneumonia, Severe Pneumonia
Fulminant Severe CAP - an Observational Study
Severe community-acquired pneumonia (CAP) represents a major cause of hospital mortality. Among severe CAP cases, some exhibit a rapidly progressive evolution, leading to severe ARDS/acute respiratory failure and septic shock…
- Conditions
- Community-acquired Pneumonia, Severe Pneumonia, ARDS, Human, Sepsis
- Trial name
- FULMISCAP (NCT06516601)
- Testing
- no intervention
- Where
- 2 sites in Italy
- Volunteers
- 1,460 people
- Sponsor
- University of Trieste
Infant, Newborn, Hypertension, Pulmonary
Early Inhaled Nitric Oxide for Respiratory Failure in Newborns
This prospective, randomized controlled trial tested whether initiating iNO therapy earlier would reduce death and reduce the use of extracorporeal membrane oxygenation (ECMO) -- temporary lung bypass -- therapy compared with the…
- Conditions
- Infant, Newborn, Hypertension, Pulmonary, Persistent Fetal Circulation Syndrome, Pneumonia, Aspiration
- Trial name
- Early iNO (NCT00005773)
- Testing
- Inhaled Nitric Oxide, Standard iNO therapy
- Where
- 18 sites in United States
- Volunteers
- 302 people
- Sponsor
- NICHD Neonatal Research Network
SARS-CoV 2, COVID
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19
Brief Summary: SARS-CoV-2 virus infection is known to cause Lung Injury that begins as dyspnea and exercise intolerance, but may rapidly progress to Critical COVID-19 with Respiratory Failure and the need for noninvasive or…
- Conditions
- SARS-CoV 2, COVID, ARDS, ALI
- Trial name
- AVICOVID-3 (NCT05137795)
- Testing
- ZYESAMI™ (aviptadil acetate)
- Sponsor
- APR Applied Pharma Research s.a.
Severe Influenza, Intensive Care (ICU)
Early Corticosteroids in Severe Influenza Pneumonia
This is a Phase III, multicentre, randomized, controlled, double-blind, superiority trial aiming to evaluate the efficacy of dexamethasone versus placebo in patients admitted to intensive care or intermediate care with influenza…
- Conditions
- Severe Influenza, Intensive Care (ICU), Reanimation, Infectious Diseases
- Trial name
- ECSIP (NCT07786662)
- Testing
- Dexametasone
- Where
- 48 sites in France
- Volunteers
- 544 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
COVID-19 Acute Respiratory Distress Syndrome, Sedation Complication
Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19
Many questions about management of COVID-19 are still not answered. So, we recruit this study aiming to evaluate improvement of oxygenation in COVID-19 patients with severe ARDS, to improve morbidity and mortality of ICU covid…
- Conditions
- COVID-19 Acute Respiratory Distress Syndrome, Sedation Complication, ICU Acquired Weakness
- Trial name
- NCT04922814
- Testing
- muscle relaxation
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
Extracorporeal Membrane Oxygenation Complication, ARDS (Acute Respiratory Distress Syndrome)
RECOMMEND Platform Trial
The goal of this platform trial is to determine the efficacy, safety and cost-effectiveness of various interventions in patients with acute cardiorespiratory failure requiring extracorporeal membrane oxygenation (ECMO) The main…
- Conditions
- Extracorporeal Membrane Oxygenation Complication, ARDS (Acute Respiratory Distress Syndrome), Intensive Care Medicine, Cardiac Arrest (CA)
- Trial name
- RECOMMEND (NCT06526533)
- Testing
- Liberal RBC Transfusion, Restrictive RBC Transfusion
- Where
- 3 sites in Australia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
Covid19, Severe Acute Respiratory Syndrome
Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19
Pilot clinical trial, with a marketed drug -natural component of human plasma-, not approved for this indication, single-center, exploratory, open, randomized, controlled, to study the efficacy and safety of human Antithrombin in…
- Conditions
- Covid19, Severe Acute Respiratory Syndrome, Distress Respiratory Syndrome
- Trial name
- NCT04745442
- Testing
- Antithrombin + best available treatment, Best available treatment
- Where
- Spain
- Volunteers
- 48 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
COVID-19 Severe Pneumonia, Acute Lung Injury
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute…
- Conditions
- COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Trial name
- NCT04369469
- Testing
- Ravulizumab, BSC
- Where
- 39 sites in United States, France and 3 more
- Volunteers
- 202 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Acute Respiratory Distress Syndrome
A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19
This is a study in adults with severe breathing problems because of COVID-19. People who are in hospital on breathing support can participate in the study.
- Trial name
- TRISTARDS (NCT04640194)
- Testing
- Standard of care, Alteplase low dose, Alteplase high dose
- Where
- 37 sites in Austria, Belgium and 11 more
- Volunteers
- 104 people
- Sponsor
- Boehringer Ingelheim
Influenza, Severe Acute Respiratory Distress Syndrome
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study
This study will examine the safety of an experimental medication called Poly-ICLC, developed for preventing or reducing the severity of infections from influenza and other viruses acquired through the nose, mouth and lungs.
- Conditions
- Influenza, Severe Acute Respiratory Distress Syndrome, Smallpox, Ebola
- Trial name
- NCT00646152
- Testing
- Poly-ICLC
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sepsis Related Acute Lung Injury/Acute Respiratory Distress Syndrome
EVLWI Exhibits Pulmonary and Systemic Permeability in Sepsis Related ALI/ARDS
To investigate the possible mechanisms of pulmonary and systemic permeability change including cytokine, extravascular lung water index (EVLWI), and oxygenation parameters in patients with sepsis related acute lung injury…
- Trial name
- NCT01694147
- Testing
- PiCCO monitoring system
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chang Gung Memorial Hospital
Severe Acute Respiratory Syndrome Coronavirus 2, Electric Impedance
Prone Positioning and Regional Ventilation in Mechanically Ventilated COVID-19 Patients
The consensus therapeutic strategy implies that COVID patients with acute lung injury due to coronavirus are routinely placed in prone position in an attempt to improve oxygenation by increasing ventilation homogeneity.
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, Electric Impedance, Prone Positioning
- Trial name
- COVID-19_EIT (NCT04359407)
- Testing
- Prone positioning
- Where
- Switzerland
- Volunteers
- 29 people
- Sponsor
- Walid HABRE
Respiratory Distress Syndrome
Effects of Bolus Surfactant Therapy on Peripheral Perfusion Index and Tissue Carbon Monoxide
Exogenous bolus surfactant administration may affect hemodynamic parameters and peripheral perfusion. Surfactant therapy is commonly used for respiratory distress syndrome in premature infants, which is also associated with…
- Trial name
- NCT01923844
- Testing
- exogenous surfactant
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people
- Sponsor
- Ege University
COVID-19
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients
The primary purpose of Stage-I of this study is to evaluate the safety and tolerability of OP-101 in patients with severe COVID-19 and of Stage 2 of this study is to evaluate the efficacy of OP-101 in patients with severe…
- Trial name
- PRANA (NCT04458298)
- Testing
- OP-101
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Ashvattha Therapeutics, Inc.
Respiratory Distress Syndrome, Mechanical Ventilation
Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19)
This is a prospective, randomized, single-center, open-label controlled trial, designed to compare the efficacy of two ventilation strategies (Low Tidal Volume and positive end-expiratory pressure (PEEP) based on the Acute…
- Conditions
- Respiratory Distress Syndrome, Mechanical Ventilation, SARS (Severe Acute Respiratory Syndrome)
- Trial name
- COVEN (NCT04497454)
- Testing
- EIT-Group, ARDSNet
- Where
- Brazil
- Volunteers
- 128 people
- Sponsor
- University of Sao Paulo General Hospital
Ventilator Associated Pneumonia
Low Versus High Corticosteroid Use in Ventilator Associated Pneumonia
patients who had >3 on Murray score and >6 on CPIS allocated randomly in two groups 120 patients in each. Group A received 30 mg/kg methyl-prednisolone slowly intravenous in 250 mL normal saline every 8 hours for only 48 hours…
- Trial name
- NCT04467892
- Testing
- methylprednisolone, Methyl Prednisolonate, ventilators
- Where
- Saudi Arabia
- Volunteers
- 240 people
- Sponsor
- King Abdul Aziz Specialist Hospital
Covid-19, Respiratory Distress Syndrome
Vitamin D Supplementation and Clinical Outcomes in Severe COVID-19 Patients
Single center, open label randomized clinical trial. Study location: tertiary hospital center (University Hospital Split, Croatia).
- Conditions
- Covid-19, Respiratory Distress Syndrome, Vitamin D Deficiency
- Trial name
- NCT05384574
- Testing
- cholecalciferol
- Where
- Croatia
- Volunteers
- 200 people
- Sponsor
- University Hospital of Split
COVID-19 Pneumonia, COVID-19 Respiratory Infection
A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of EOM613, a peptide nucleic acid with novel immune-modulating properties, in treating patients with severe COVID-19 infections.
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05212532
- Testing
- EOM613
- Where
- 4 sites in Brazil
- Volunteers
- 40 people
- Sponsor
- EOM Pharmaceuticals
ARDS, Septic Shock
Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation
to evaluate the effect of use of bronchoscopy in the course of sepsis, weaning from the ventilator, duration of ICU stays and mortality rate in septic patients with ARDS due to VAP.
- Trial name
- NCT06072248
- Testing
- Meropenem, bronchoscopy, ventilator
- Where
- Saudi Arabia
- Volunteers
- 200 people
- Sponsor
- King Abdul Aziz Specialist Hospital